REFRACTORY GLAUCOMA TREATMENT MARKET ANALYSIS
Key Developments
Key players in the market are focused on launching new devices to expand their product portfolio. For instance, in August 2019, New World Medical, Inc., a privately held ophthalmic company launched Ahmed ClearPath glaucoma drainage device.
In June 2019, Glaukos Corporation announced that standalone implantation of its iStent inject Trabecular Micro-Bypass System achieved substantial reduction in mean intraocular pressure in glaucoma treatment.
Key players in the market are also focused on adopting acquisition strategies to expand their product portfolio. For instance, in June 2019, Glaukos Corporation acquired DOSE Medical Corporation, a company focused on developing multiple micro-invasive, bioerodible, sustained-release drug delivery platforms for the treatment of various retinal diseases, including refractory glaucoma.
Need a Custom Report?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now
Credibility and Certifications
9001:2015
27001:2022
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
U.S.: 
U.K. : 
India : 